Francis Knuettel II - 02 Jul 2025 Form 4 Insider Report for Pelthos Therapeutics Inc. (CHRO)

Reporting relationship: CFO, Treas & Secty
Issuer ticker: CHRO
Reported as of: 02 Jul 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 07 Jul 2025, 21:44:42 UTC
Prior SEC filing: 03 Jul 2025
Next SEC filing: 06 Oct 2025
Source filing: View source filing
Reporting owner signature: /s/ Francis Knuettel II

Key filing fact

Francis Knuettel II filed Form 4 for Pelthos Therapeutics Inc. (CHRO) on 07 Jul 2025.

Key facts

This page summarizes Francis Knuettel II's Form 4 filing for Pelthos Therapeutics Inc. (CHRO).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 07 Jul 2025, 21:44.

Change

Previous filing in this sequence was filed on 03 Jul 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001433316 Primary reporting owner

Francis Knuettel II

Relationship: CFO, Treas & Secty
Address: C/O PELTHOS THERAPEUTICS INC., 4020 STIRRUP CREEK DRIVE, SUITE 110, DURHAM
Signature: /s/ Francis Knuettel II
Signature date: 07 Jul 2025

This filing has been restated. Open the amended filing.

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PTHS transaction Derivative

Restricted Stock Units

Award

Transaction value
Shares: +33,472
Change %
Price
Shares after: 33,472
Date: 02 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 33,472
Exercise price: $13.50
Footnotes: F1

PTHS transaction Derivative

Stock Option

Award

Transaction value
Shares: +102,000
Change %: +237%
Price
Shares after: 145,074
Date: 02 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 102,000
Exercise price: $13.50
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

On July 2, 2025, the Reporting Person was granted restricted stock units to purchase 33,472 shares of common stock at an exercise price of $13.50 per share, with the initial one third (1/3) of such shares vesting on July 2, 2026, and in equal installments on a quarterly basis thereafter over a period of two (2) years.

Footnote F2

On July 2, 2025, the Reporting Person was granted stock options to purchase 102,000 shares of common stock at an exercise price of $13.50 per share, with the initial one third (1/3) of such shares vesting on July 2, 2026, and quarterly thereafter in equal installments over a period of two (2) years.

Footnote F3

The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.